The WATCHMAN™ portal is an educational resource for use by practicing physicians and allied healthcare professionals. The WATCHMAN portal is not intended for patients or consumers. WATCHMAN FLX Device Product Brochure File Type: PDF Brochure discusses why WATCHMAN FLX device is a safe and effective...
WATCHMAN Download Center The WATCHMAN™ portal is an educational resource for use by practicing physicians and allied healthcare professionals. The WATCHMAN portal is not intended for patients or consumers. Welcome to the WATCHMAN Download Center. With your partnership, WATCHMAN Device has changed the...
WATCHMAN Download Center The WATCHMAN™ portal is an educational resource for use by practicing physicians and allied healthcare professionals. The WATCHMAN portal is not intended for patients or consumers. Welcome to the WATCHMAN Download Center. With your partnership, WATCHMAN Device has changed the...
*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA. †Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke...
Patients meeting the inclusion criteria with CHA 2 DS 2 -VASc score2 and who are deemed by 2 study physicians to be unsuitable for OAC will be randomized in a 2:1 allocation ratio to Watchman versus control. Control patients will be prescribed single antiplatelet therapy or no therapy at ...
area of the heart where stroke-causing blood clots commonly form. This technology, which is built upon the most studied and implanted LAAC device in the world, features a new, fully rounded design that offers physicians the ability to safely enter, and maneuver within, the left atrial ...
E. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133, 546S-592S (2008). Connolly, S. J. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (...
controlled healing and endothelization of the device surface. In addition, newly added visualization markers are intended to enhance device placement for optimal sealing around the LAA. This device is also available in a new 40mm size option, which will enable physicians to treat a broader range ...
“The robust clinical evidence and successful commercial outcomes of the WATCHMAN device to-date reinforce the value of this procedure for all appropriate patients.” It comes with a fully enclosed and rounded frame to enable implantation flexibility for customising the placement. Physicians will be ...
systemic embolism based on CHADS2 or CHA2DS2-VASc scores; are deemed by their physicians to be suitable for warfarin; and have an appropriate rationale to seek a nonpharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared with warfarin."[1] ...